Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (321)	6/28/2007 3:44:24 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

Well, the bottom line is you nibble because it is cheap--and if they merge their repositioning service with more stuff, maybe they can make a go of it. There seems to be no lack of VC backed startups that are making initial stabs into "systems biology" and I could see glgc evolving into something like that. It isn't enough to sacrifice a lot of mice and rats, they should want to get in on stratifying clinical trials and such. You reposition the drug into the right people, not just the right biologic pathway. CLDA was mentioned in an article just the other day, and that might very well be a better choice than glgc (it certainly has a lot of familiar names under that roof). However, once you start working up the food chain, from glgc or, say, pre-IPO companies...to CLDA...to Celera...to Quest Diagnostics or PPDI, the whole propositon gets a little silly doesn't it? GLGC pretty much needs new management to do a CLDA etc. Don't you think? And they really might not have enough cash anyway to do these things. Pfizer has the cash to do these things, but that's no fun.